EP4199900A1 - Composition et formulation pour le traitement de la constipation et du ballonnement abdominal - Google Patents

Composition et formulation pour le traitement de la constipation et du ballonnement abdominal

Info

Publication number
EP4199900A1
EP4199900A1 EP20790080.4A EP20790080A EP4199900A1 EP 4199900 A1 EP4199900 A1 EP 4199900A1 EP 20790080 A EP20790080 A EP 20790080A EP 4199900 A1 EP4199900 A1 EP 4199900A1
Authority
EP
European Patent Office
Prior art keywords
composition
hereinbefore
formulation
weight
expulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20790080.4A
Other languages
German (de)
English (en)
Inventor
Sara Pezzetta
Elena VATRI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biofarma SRL
Original Assignee
Biofarma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biofarma SRL filed Critical Biofarma SRL
Publication of EP4199900A1 publication Critical patent/EP4199900A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals

Definitions

  • the present invention concerns a granular or powder composition for treating constipation and abdominal bloating, as well as a formulation which comprises the same composition.
  • Constipation is a common gastrointestinal disorder widespread throughout the world that affects both the adult and the child population.
  • constipation (costiveness) defines a syndrome generally associated with persistent difficulties or discomfort in the area of alvine functions. It is characterized by reduced frequency of defecation, difficulty in evacuating with the emission of hard and pellet-like stools, associated in a variable extent with a sensation of incomplete evacuation, a sensation of rectal-anal obstruction, a sensation of distension or abdominal pain or bloating.
  • Constipation is often accompanied by other symptoms of a gastrointestinal nature, including abdominal pain and distension and bloating, due to an excess of gas. In fact, if the stools remain in the intestine for a prolonged period, this leaves the intestinal flora more time for fermentation, with consequent hyper-production of gas.
  • the causes of constipation can be various and multifactorial. Constipation can be classified into primary or secondary constipation, on the basis of etiology. Primary or organic causes of constipation are the alterations of the neuromuscular mechanisms responsible for the control of gastrointestinal and anorectal functions, while secondary causes are linked to metabolic disorders, the intake of certain medicines, neurological disorders and primary diseases of the colon.
  • laxatives are also known, which have an impact on the transfer of water and electrolytes through the intestinal mucosa; they soften hardened stools and stimulate defecation.
  • laxatives can be divided into various types, the main ones being bulk-forming laxatives, lubricating laxatives, stimulating laxatives and osmotic laxatives.
  • Bulk-forming laxatives increase the volume of the non-absorbable solid residue, bringing considerable quantities of indigestible substances, in particular food fibers, which swell in contact with water. These laxatives make the stools denser and more voluminous and increase the amount of water they retain, which promotes evacuation.
  • Lubricating laxatives mix with the fecal matter, helping to soften and lubricate it. In this way, they facilitate the transit of the stools into the intestine by sliding.
  • Stimulating laxatives increase intestinal motility, in particular colic contractions to promote the progress of the stools toward the outside.
  • Osmotic laxatives are not absorbed but retain water and electrolytes in the colon, affecting the consistency of the stools so as to make them semi-solid or liquid.
  • Osmotic laxatives are the most frequently prescribed type of laxative, not only in the case of acute and chronic constipation, but also in preparation for diagnostic tests (e.g. colonoscopy) or surgery.
  • Osmotic laxatives comprise complex carbohydrates, such as lactulose or mannitol, or saline substances such as magnesium hydroxide or phosphates, or even polyethylene glycols (PEG), which are inert water-soluble polymers often with a high molecular weight.
  • complex carbohydrates such as lactulose or mannitol
  • saline substances such as magnesium hydroxide or phosphates, or even polyethylene glycols (PEG), which are inert water-soluble polymers often with a high molecular weight.
  • PEG polyethylene glycols
  • one purpose of the present invention is to propose a composition for treating constipation and abdominal bloating which can alleviate unwanted side effects, both in the short term and in the long term.
  • Another purpose of the present invention is to provide a formulation for treating constipation and abdominal bloating which is convenient and simple for users to take.
  • the Applicant has devised, tested and embodied the present invention to overcome the shortcomings of the state of the art and to obtain these and other purposes and advantages.
  • compositions and of a formulation for treating constipation and abdominal bloating are described, which overcome the limits of the state of the art and eliminate the defects present therein.
  • a granular or powder composition for treating constipation and abdominal bloating comprising a polyethylene glycol and an anti-foaming agent.
  • the polyethylene glycol is present in a quantity greater than or equal to 95% by weight of the total weight of the composition. More favorably, the polyethylene glycol has a concentration comprised between 95% and 99% by weight of the total weight of the composition.
  • the weight ratio between polyethylene glycol and simethicone PEG: Simethicone is greater than 90:1, more advantageously it is comprised between 99:1 and 140:1, even more advantageously it is comprised between 100:1 and 130:1.
  • the polyethylene glycol is macrogol, and has a molecular weight preferably comprised between 3000 and 5000 Da, more preferably equal to 3350 Da or 4000 Da.
  • the anti-foaming agent is dimethicone, preferably in activated form.
  • the dimethicone can be activated, for example by adding silicon oxide gel.
  • a specific example of dimethicone in activated form is simethicone.
  • the composition also comprises a sweetener.
  • the sweetener is an artificial sweetener, for example sucralose.
  • the composition can also comprise at least one insoluble fiber, or a mixture of insoluble fibers and/or soluble fibers, in order to increase the fecal mass and promote its expulsion.
  • the composition also comprises a bulk-forming laxative, more preferably a hydrophilic resin, even more preferentially polycarbophil calcium, in order to further promote the expulsion of the fecal mass and increase the elimination of gases.
  • a bulk-forming laxative more preferably a hydrophilic resin, even more preferentially polycarbophil calcium, in order to further promote the expulsion of the fecal mass and increase the elimination of gases.
  • the composition also comprises a stool softening substance, in order to promote the expulsion of the fecal mass.
  • the stool softening substance comprises mineral oil, vegetable oil and/or docusate sodium.
  • composition described here also comprises one or more magnesium mineral salts, in order to promote the expulsion of the fecal mass.
  • composition for treating constipation and abdominal bloating described here can also comprise an anti-caking agent, for the correct absorption and the correct dispersion of the activated dimethicone and to promote the fluidity of the powdered preparation.
  • an anti-caking agent is silicon dioxide.
  • composition also comprises specific enzymes, for example amylase and/or glycosidases.
  • the composition described here also comprises muco-polysaccharides in order to create a protective layer in the intestinal lumen and promote the expulsion of the fecal mass.
  • the muco-poly saccharide comprises hyaluronic acid and its salts.
  • composition described here also comprises a probiotic (even tyndalized) in order to contribute to the digestive process, and consequently promote the expulsion of the fecal mass and, at the same time, rebalance the intestinal bacterial flora.
  • a probiotic even tyndalized
  • the composition described here also comprises plant extracts titrated in polysaccharides, with calming, moisturizing, and soothing functions and a function of filming the intestinal mucosa, such as for example titrated polysaccharides extracted from Mallow, Altea, Linden.
  • the composition described here also comprises carboxymethylcellulose as a filming and protective agent of the intestinal lumen.
  • the composition described here also comprises vegetable and mineral oils with a lubricating and softening action on stools.
  • the composition described here also comprises sugar alcohols such as xylitol, glycerol, sorbitol, used to promote the organoleptic pleasantness of the preparation as well as because of their characteristics of recalling water and softening stools.
  • sugar alcohols such as xylitol, glycerol, sorbitol
  • the granular or powder composition described here comprises macrogol, activated dimethicone (for example simethicone), an anti-caking agent and a sweetener.
  • the anti-caking agent is silicon dioxide.
  • the sweetener is sucralose.
  • the macrogol has a concentration greater than 40%, preferably greater than 50%, more preferably greater than 95% by weight of the total weight of the composition
  • the activated dimethicone has a concentration comprised between 0.05% and 2.0% by weight
  • the anti-caking agent, where present has a concentration comprised between 0.05% and 2.0% by weight
  • the sweetener has a concentration lower than 0.5% by weight.
  • a formulation for treating constipation and abdominal bloating, which comprises the granular or powder composition indicated above.
  • the formulation is preferably in powder or granular form, preferably soluble in water or other liquids, it is made available as a gel or it is made available in a liquid solution for oral administration.
  • the formulation is made available as a gel, it also comprises viscosifying/texturizing rheological agents such as guar gum, xanthan gum, carboxymethylcellulose (CMC) and/or carbopol. These compounds allow to obtain the formulation as a gel.
  • viscosifying/texturizing rheological agents such as guar gum, xanthan gum, carboxymethylcellulose (CMC) and/or carbopol.
  • the formulation is made available in single-dose sachets or in multi-dose packs.
  • the present description also includes the intervals that derive from uniting or overlapping two or more intervals described, unless otherwise indicated.
  • the present description also includes the intervals that can derive from the combination of two or more values taken at different points, unless otherwise indicated.
  • Embodiments described here concern a composition for treating constipation and abdominal bloating comprising a PEG compound, in particular macrogol, both as a laxative agent as well as a main ingredient.
  • Macrogol represents more than 40% by weight of the composition, preferably more than 45%, more preferably more than 50%, even more preferably more than 95% by weight.
  • macrogol is present between 45% and 99% by weight of the composition, in particular between 95% and 99% by weight of the total weight of the composition.
  • Macrogol is a high molecular weight water-soluble inert polymer, capable of forming hydrogen bonds with water molecules, operating as a pure osmotic agent, which retains the water that accompanies administration in stools and opposes its reabsorption in the large intestine.
  • the mechanism through which macrogol acts determines a rehydration and softening of the stools, thus facilitating defecation.
  • Intestinal transit is accelerated in the colon and rectum since macrogol promotes the intraluminal movement of stools with a reduced consistency due to the increase in water content.
  • the increase in stool volume dilates the intestinal wall, accelerating intestinal transit in the colon and rectum and activating the urge to defecate.
  • Macrogol therefore acts simultaneously on the main symptoms of constipation, increasing the frequency of bowel movements and reducing the consistency of the stools. Macrogol is not absorbed or metabolized in the intestinal tract and does not lead to electrolyte imbalances, if taken with the indicated dose of liquid. The mode of action of macrogol is non-specific and is independent of the pathogenesis of the disorders.
  • Macrogol has a molecular weight preferably comprised between 3000 Da and 5000 Da. More particularly, the macrogol comprised in the composition according to the invention can have a molecular weight of 3350 Da or 4000 Da. These two types of macrogol differ only in terms of the molecular weight, since they are identical in all other characteristics, in particular in terms of efficacy and safety profile.
  • electrolyte-free macrogol-based products represents an effective and safe treatment for constipation and does not lead to electrolyte imbalances, both in adults and also in children. Therefore, it does not cause side effects following its intake and, therefore, can be considered a safe and well tolerated active ingredient.
  • composition according to the invention also comprises an anti-foaming agent, in particular dimethicone, preferably activated with the addition of silicon oxide gels.
  • an anti-foaming agent in particular dimethicone, preferably activated with the addition of silicon oxide gels.
  • activated dimethicone is simethicone.
  • Dimethicone is a silicone belonging to the family of polydimethylsiloxanes which has anti-foaming properties, which are the basis of its beneficial effects. Dimethicone has a polymeric structure consisting of a succession of silicon and oxygen atoms (polydimethylsiloxane), mixed with silica gel. The latter ingredient is hydrophobic, stable at high temperatures, physiologically inactive, non-toxic and safe when taken orally. It is not absorbed by the gastrointestinal tract and does not interfere with the digestive processes in any way whatsoever.
  • the anti-foaming action is exerted through a physical mechanism of reduction of the surface tension of the gas bubbles.
  • the mixture of polydimethylsiloxane and hydrophobic silica disperses on the surface of aqueous liquids, forming a low surface tension film that breaks easily. In this way, the gas contained in the bubbles present in the gastrointestinal tract is released and unites to form entities of a larger size (coalescence) which are easily eliminated.
  • activated dimethicone in particular simethicone, decreases the surface tension of the gas bubbles present in the gastrointestinal tract, facilitating their expulsion.
  • the elimination of gases reduces the sensation of bloating and abdominal distension.
  • dimethicone does not cause any side effects whatsoever following its intake, and therefore can be considered a safe and well-tolerated agent.
  • Numerous clinical studies have shown the efficacy and safety of using dimethicone in reducing the symptoms caused by excess gas in the intestine, regardless of its causes.
  • the activated dimethicone supports the main action of the composition, given by macrogol, and helps relieve the discomfort caused by bloating and flatulence, gastrointestinal symptoms that often accompany constipation.
  • dimethicone in particular activated dimethicone (for example simethicone) is present in a concentration comprised between 0.05% and 2%, more preferably between 0.1% and 1% of the composition.
  • activated dimethicone for example simethicone
  • constipation is often accompanied by gastrointestinal symptoms (including abdominal distention, meteorism, and flatulence) caused by excess gas. Gas is formed as a consequence of the prolonged stay of the stools in the intestine, which gives the intestinal bacterial flora more time for fermentation.
  • macrogol-based solutions can also be accompanied by flatulence and abdominal bloating.
  • activated dimethicone as a secondary ingredient in macrogol-based formulations for the asymptomatic treatment of constipation helps to alleviate the discomfort caused by these symptoms, without interfering in any way whatsoever with the main mechanism of action of the product that is conferred by macrogol.
  • the granular or powder composition described here, or the formulation comprising such composition can include one or more prebiotic and/or probiotic compounds.
  • prebiotic compounds such as one or more insoluble fibers
  • insoluble fibers include Psyllium cuticle or oat bran.
  • the one or more insoluble fibers it can also be provided to add one or more soluble fibers to the composition.
  • fibers include inulin, pectin, fructooligosaccharides (FOS) or psyllium seeds.
  • the expulsion of the fecal mass can be further promoted by adding, as optional compounds, at least one or more from calcium polycarbophil, which also increases the elimination of gases, mineral oil or docusate sodium as softening substances of the fecal mass, one or more from magnesium mineral salts, amylase and/or glycosidase type enzymes, hyaluronic acid as mucus- polysaccharide which create a protective layer in the intestinal lumen.
  • a probiotic which, in addition to promoting the expulsion of fecal matter, also has an action of rebalancing the intestinal bacterial flora.
  • an anti-caking excipient such as silicon dioxide
  • silicon dioxide has a concentration comprised between 0.05% and 2% by weight, more preferably between 0.1% and 1% by weight of the composition.
  • an artificial sweetener can be used.
  • an artificial sweetener is sucralose, but acesulfame K, aspartame or stevia, or a mixture of one or more of them can also be provided.
  • the sweetener is preferably concentrated to less than 0.5%, more preferably less than 0.1% by weight in the composition described here. It can also be provided to add a flavoring excipient, for example containing an orange flavor, a lemon flavor or any type of flavor whatsoever that has a pleasant taste.
  • composition can also advantageously contain carboxymethylcellulose CMC as a filming agent, plant extracts titrated in polysaccharides and/or sugar alcohols.
  • salts or electrolytes
  • the addition of electrolytes derives from their original use as solutions for bowel preparation before performing diagnostic tests or surgery.
  • the macrogol-based composition is to be administered in high doses and salts are added in order to limit the risk of hydro-electrolyte imbalances.
  • composition for treating constipation and abdominal bloating described here is advantageously formulated in granular or powder form, or in a gel or in a liquid solution for oral administration. Regardless of the formulation of the composition, it can be made available in single-dose sachets or in multi-dose packs (for example ajar or bottle).
  • the formulation can be packaged into stick-pack type sachets (for example the sachet known as T-Win® supplied by the Applicant), in turn packaged into a secondary packaging, for example a cardboard box.
  • a secondary packaging for example a cardboard box.
  • the singledose sachets can contain, for example, 4 g, 5 g and 10 g of powder or 10 ml or 20 ml of oral solution.
  • a multi-dose package can be provided, such as, for example, a jar or a bottle in which a predeterminate quantity of product is disposed.
  • a metering member typically a measuring cup, configured to take the correct dose of formulation.
  • the multi-dose package can contain, for example, 200 g, 250 g, 300 g, 400 g of powder or 480 ml of oral solution, depending on requirements.
  • the powder or granules should be diluted in water or other liquid and taken immediately.
  • the oral solution should be taken as it is and then followed by water.
  • the volumes of water or other liquids to be used for intake are predefined.
  • the doses are defined taking into account the population being treated and are specified as a function of age group and, in the case of children aged between 6 months and 12 years, also of the different weight brackets.
  • the dose should be increased or decreased, depending on the individual response to treatment, in order to allow a regular evacuation of soft stools.
  • the maximum dose provided does not normally exceed 20 g of powder or 40 ml of oral solution in the versions intended for children under the age of 12, and 40 g of powder or 80 ml of oral solution in the versions intended for adults and children over the age of 12.
  • compositions for treating constipation and abdominal bloating are given below.
  • EXAMPLE 1 The following composition is formulated in powder form and does not contain any flavoring excipient whatsoever. It comprises:
  • dimethicone 0.800 % (w/w)
  • Silicon dioxide 1.000 % (w/w)
  • composition is also formulated in powder form, and comprises one flavoring excipient.
  • dimethicone 0.800 % (w/w)
  • Silicon dioxide 1.000 % (w/w)
  • This example provides a liquid formulation of the composition according to the invention, and does not contain flavoring excipients. Since it is a liquid formulation, a solubilizing component such as polysorbate 80 is provided.
  • Citric acid 0.334 % (w/w)
  • this liquid formulation was obtained by diluting a powder formulation in which Macrogol is concentrated at 95.394% (w/w).
  • This example shows a liquid formulation of the composition, with a flavoring excipient. Since it is a liquid formulation, a solubilizing component such as polysorbate 80 is provided. Purified water 51.299 % (w/w)
  • Citric acid 0.334 % (w/w)
  • this liquid formulation was obtained by diluting a powder formulation in which Macrogol is concentrated at 95.002% (w/w).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La composition granulaire ou pulvérulente pour le traitement de la constipation et du ballonnement abdominal comprend au moins un polyéthylène glycol PEG en tant qu'agent laxatif et un agent anti-météorisme. Une telle composition est mise à disposition dans une formulation qui peut être une poudre, dans une solution pour une administration orale ou un gel.
EP20790080.4A 2020-08-20 2020-08-20 Composition et formulation pour le traitement de la constipation et du ballonnement abdominal Pending EP4199900A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IT2020/000061 WO2022038643A1 (fr) 2020-08-20 2020-08-20 Composition et formulation pour le traitement de la constipation et du ballonnement abdominal

Publications (1)

Publication Number Publication Date
EP4199900A1 true EP4199900A1 (fr) 2023-06-28

Family

ID=72840602

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20790080.4A Pending EP4199900A1 (fr) 2020-08-20 2020-08-20 Composition et formulation pour le traitement de la constipation et du ballonnement abdominal

Country Status (2)

Country Link
EP (1) EP4199900A1 (fr)
WO (1) WO2022038643A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100297264A1 (en) * 2007-10-17 2010-11-25 Thomas Jefferson University Bowel purgative and uses thereof
DE102012024434A1 (de) * 2012-12-14 2014-06-18 Regalismons S.A. Verstärkung der entschäumenden Wirkung von Polysiloxanen, zugehöriger Zusammensetzungen und Lösungen

Also Published As

Publication number Publication date
WO2022038643A1 (fr) 2022-02-24

Similar Documents

Publication Publication Date Title
US10596135B2 (en) Method, composition and package for bowel cleansing
JP7277396B2 (ja) Ｐｅｇとアスコルビン酸塩とを含む組成物
JP5872573B2 (ja) ポリエチレングリコール含有製剤
FI105153B (fi) Menetelmä farmaseuttisten, suun kautta annettavien dideoksipuriininukleosidikoostumusten valmistamiseksi
US7026298B2 (en) Oral rehydration compositions
PT1663257E (pt) Utilização de laxantes para tratamento da síndrome do cólon irritável
US20020085990A1 (en) Effervescent laxatives
TW200930385A (en) Composition with active ingredient combination for the treatment of constipation
EP4199900A1 (fr) Composition et formulation pour le traitement de la constipation et du ballonnement abdominal
US10617761B2 (en) Compositions and solutions for colon cleansing
CN110721151B (zh) 一种西甲硅油复方液体组合物及其制备方法和应用
WO1994005273A1 (fr) Compositions gastro-intestinales contenant du dimethylsulfone et du dimethylsulfoxyde
EP3586832B1 (fr) Composition pharmaceutique pour le traitement de la constipation
CA2362355A1 (fr) Laxatifs effervescents
JPH09505824A (ja) 便秘の治療におけるジメチコーンの使用
ES2633445T3 (es) Composición para usar como laxante
WO2019227747A1 (fr) Solution orale d'oligosaccharides de chitosane et son procédé de préparation
CN115554361B (zh) 一种治疗过敏性鼻炎的中药组合物及其药剂和应用
Thompson Constipation and catharsis.
WO2021090345A1 (fr) Composition et formulation pour le traitement de gaz et de ballonnement intestinaux
JP6355806B1 (ja) ラクツロースを有効成分とする便秘症治療剤
CN114642631A (zh) 一种通便口服液及其制备方法
JP2012102036A (ja) 便通改善用組成物及びそれを含有する飲食品およびその使用方法
JP2007210951A (ja) 腸内環境改善用組成物及びそれを含有する飲食品

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230317

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230628

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240410